This strategy was first reported in VV, which encodes a secretory bispecific T-cell engager consisting of two single-chain variable fragments specific for CD3 and the tumor cell surface antigen EphA2 (EphA2-T-cell engager-armed VV (EphA2-TEA-VV)), and showed potent antitumor activity in comparison with control VV plus T cells in a lung cancer xenograft model (128). Here, EPHA2 is linked to lung carcinoma.